Literature DB >> 23607285

Combined low-frequency ultrasound and microbubble contrast agent for the treatment of benign prostatic hyperplasia.

Shao-ling Yang1, Ke-qiang Tang, Wen-kun Bai, Yi-Wen Zhao, E Shen, Jun-jia Tao, Bing Hu.   

Abstract

BACKGROUND AND
PURPOSE: Benign prostatic hyperplasia is one of the most common conditions in middle-aged and elderly men. The aim of the study was to investigate the treatment effects of low-frequency ultrasound combined with a microbubbles agent on benign prostatic hyperplasia.
METHODS: Eighteen 7-year-old male beagles with prostatic hyperplasia were randomly divided into six groups (n=3): Control group, 21 kHz ultrasound group, 21 kHz ultrasound and microbubble contrast agent group, 1 MHz ultrasound group, 1 MHz ultrasound and microbubble contrast agent group, and microbubble contrast agent group. The histopathologic damage to prostate cells was assessed via transmission electron microscopy and optical microscopy. The protein expressions of prostate-specific antigen (PSA), inducible nitric oxide synthase (iNOS), and super oxidase dimutase (SOD) were detected by enzyme-linked immunosorbent assay. Levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and creatinine (Cr) were detected by the Biochemistry Automatic Analyzer.
RESULTS: Significant tissue injury, mitochondria injury, and cell apoptosis were observed in 21 kHz ultrasound and the microbubble contrast agent group. Compared with the control and microbubbles contrast agent groups, the decrease in levels of PSA or increase in levels of iNOs and SOD in the other four groups were statistically significant (P<0.05). The lowest level of PSA and the highest levels of iNOs and SOD were observed in the 21 kHz ultrasound and microbubbles contrast agent group. No significant changes in levels of AST, ALT, BUN, and Cr were observed between the six groups.
CONCLUSIONS: Our results suggest that lower frequency ultrasound may have a better effect on benign prostatic hyperplasia, and microbubble contrast agent application further strengthens this biological effect.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23607285      PMCID: PMC3741423          DOI: 10.1089/end.2012.0637

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  29 in total

1.  Microbubble-enhanced cavitation for noninvasive ultrasound surgery.

Authors:  Binh C Tran; Jongbum Seo; Timothy L Hall; J Brian Fowlkes; Charles A Cain
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2003-10       Impact factor: 2.725

Review 2.  Ultrasound microbubble contrast agents for diagnostic and therapeutic applications: current status and future design.

Authors:  Shih-Tsung Kang; Chih-Kuang Yeh
Journal:  Chang Gung Med J       Date:  2012 Mar-Apr

3.  [Clinical management of patient with benign prostatic hyperplasia in Spain].

Authors:  J M Cozar; E Solsona; F Brenes; A Fernández-Pro; F León; J M Molero; J F Pérez; M P Rodríguez; A Huerta; I Pérez-Escolano
Journal:  Actas Urol Esp       Date:  2011-09-28       Impact factor: 0.994

4.  An echo-contrast agent, Levovist, lowers the ultrasound intensity required to induce apoptosis of human leukemia cells.

Authors:  Hidetaka Ando; Loreto B Feril; Takashi Kondo; Yoshiaki Tabuchi; Ryohei Ogawa; Qing-Li Zhao; Zheng-Guo Cui; Shin-Ichiro Umemura; Hideki Yoshikawa; Takuro Misaki
Journal:  Cancer Lett       Date:  2005-12-27       Impact factor: 8.679

5.  Update on AUA guideline on the management of benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

Review 6.  Serenoa Repens, lycopene and selenium: a triple therapeutic approach to manage benign prostatic hyperplasia.

Authors:  L Minutoli; A Bitto; F Squadrito; H Marini; N Irrera; G Morgia; A Passantino; D Altavilla
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 7.  On the expression of nitric oxide synthase by human macrophages. Why no NO?

Authors:  J E Albina
Journal:  J Leukoc Biol       Date:  1995-12       Impact factor: 4.962

8.  Ablation of benign prostatic hyperplasia using microbubble-mediated ultrasound cavitation.

Authors:  Tao Li; Zheng Liu
Journal:  Med Hypotheses       Date:  2009-11-28       Impact factor: 1.538

9.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

10.  Evaluation of oxidative stress and DNA damage in benign prostatic hyperplasia patients and comparison with controls.

Authors:  Manzoor Ahmad; Nida Suhail; Tariq Mansoor; Naheed Banu; Shamshad Ahmad
Journal:  Indian J Clin Biochem       Date:  2012-06-12
View more
  1 in total

1.  Upregulation of Beclin-1 expression in DU-145 cells following low-frequency ultrasound irradiation combined with microbubbles.

Authors:  Y U Wang; Yi-Ni Chen; Wei Zhang; Y U Yang; E Shen; Bing Hu
Journal:  Oncol Lett       Date:  2015-07-17       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.